TCRX Q3 2023 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+15.6% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$25M-636.7% margin

Net Income

-$23M-591.6% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+23.5%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$7M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$291M

Total Liabilities

$122M

Stockholders' Equity

$169M

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$3M	+15.6%
Gross Profit	$4M	$3M	+15.6%
Operating Income	-$25M	-$17M	-49.3%
Net Income	-$23M	-$16M	-41.6%